克林沙星对来自北美10个中心的当代临床分离菌株的体外活性。
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.
作者信息
Fuchs P C, Barry A L, Brown S D
机构信息
The Clinical Microbiology Institute, Wilsonville, Oregon 97070, USA.
出版信息
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
Abstract
Clinafloxacin was more active than ciprofloxacin against 4,213 aerobic and facultative anaerobic bacterial isolates from 10 medical centers, as tested by broth microdilution and disk diffusion methods. The percentage of 201 anaerobes susceptible to clinafloxacin by broth microdilution was comparable to cefoxitin. Our data support the proposed disk diffusion interpretive criteria for aerobic bacteria with 5-microg clinafloxacin disks.
摘要
通过肉汤微量稀释法和纸片扩散法检测发现，对于来自10个医学中心的4213株需氧菌和兼性厌氧菌分离株，克林沙星比环丙沙星更具活性。通过肉汤微量稀释法检测，201株厌氧菌对克林沙星的敏感率与头孢西丁相当。我们的数据支持了针对5微克克林沙星纸片对需氧菌的纸片扩散法解释标准。
相似文献
1
In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.克林沙星对来自北美10个中心的当代临床分离菌株的体外活性。
Antimicrob Agents Chemother. 1998 May;42(5):1274-7. doi: 10.1128/AAC.42.5.1274.
2
In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.克林沙星、曲伐沙星和环丙沙星的体外活性
J Antimicrob Chemother. 1997 Aug;40(2):205-11. doi: 10.1093/jac/40.2.205.
3
In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.吉米沙星对来自北美11个医学中心的当代临床分离菌株的体外活性及纸片扩散法检测判读标准的评估。
Diagn Microbiol Infect Dis. 2000 Dec;38(4):243-53. doi: 10.1016/s0732-8893(00)00198-x.
4
Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies.采用最低杀菌浓度（MBC）试验、体外时间杀菌和体内时间杀菌研究，比较克林沙星、CI-990和环丙沙星对细菌的根除效果。
J Antimicrob Chemother. 1998 Jun;41(6):605-14. doi: 10.1093/jac/41.6.605.
5
Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals.克林沙星与其他九种化合物针对美国医院2000株当代临床分离株的比较活性。
Diagn Microbiol Infect Dis. 1999 Sep;35(1):81-8. doi: 10.1016/s0732-8893(99)00020-6.
6
Comparative activities of clinafloxacin against gram-positive and -negative bacteria.克林沙星对革兰氏阳性菌和阴性菌的比较活性。
Antimicrob Agents Chemother. 1998 May;42(5):1269-73. doi: 10.1128/AAC.42.5.1269.
7
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.莫西沙星（拜耳12-8039）对需氧临床分离株的抗菌活性及纸片药敏试验的暂行标准。
Eur J Clin Microbiol Infect Dis. 1999 Apr;18(4):305-9. doi: 10.1007/s100960050284.
8
In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.新型氟喹诺酮类药物DU-6859a与其他喹诺酮类药物及口服头孢菌素针对5086株近期临床分离株的体外比较。
J Antimicrob Chemother. 1993 Dec;32(6):877-84. doi: 10.1093/jac/32.6.877.
9
Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.氟喹诺酮类药物对25129株革兰氏阳性和革兰氏阴性临床分离株的多中心体外比较研究。
Diagn Microbiol Infect Dis. 1995 Jan;21(1):33-45. doi: 10.1016/0732-8893(94)00087-d.
10
In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.司帕沙星与环丙沙星及氧氟沙星相比对呼吸道病原体的体外活性。
Chemotherapy. 1993;39(1):32-5. doi: 10.1159/000238970.
引用本文的文献
1
A critical review of the fluoroquinolones: focus on respiratory infections.氟喹诺酮类药物的批判性综述：聚焦于呼吸道感染
Drugs. 2002;62(1):13-59. doi: 10.2165/00003495-200262010-00002.
2
Drug interactions with clinafloxacin.克林沙星的药物相互作用。
Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52. doi: 10.1128/AAC.45.9.2543-2552.2001.
3
Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.不同程度肾功能受试者的克林沙星药代动力学
Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42. doi: 10.1128/AAC.45.9.2536-2542.2001.
4
Pharmacokinetics of clinafloxacin after single and multiple doses.克林沙星单剂量和多剂量给药后的药代动力学
Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35. doi: 10.1128/AAC.45.9.2529-2535.2001.
5
In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.六种喹诺酮类药物的体外活性及金黄色葡萄球菌和凝固酶阴性葡萄球菌的耐药机制
Antimicrob Agents Chemother. 2001 May;45(5):1553-7. doi: 10.1128/AAC.45.5.1553-1557.2001.
6
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.环丙沙星与亚胺培南/西司他丁治疗腹腔内感染的临床试验结果。
Ann Surg. 2001 Jan;233(1):79-87. doi: 10.1097/00000658-200101000-00013.
7
Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.克林沙星与曲伐沙星对1000株脆弱拟杆菌属菌株的体外活性比较：培养基对试验结果的影响
Antimicrob Agents Chemother. 2000 Jun;44(6):1710-2. doi: 10.1128/AAC.44.6.1710-1712.2000.
8
In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.西他沙星（DU-6859a）及其他六种氟喹诺酮类药物对8796株临床分离菌的体外活性
Antimicrob Agents Chemother. 2000 Apr;44(4):1102-7. doi: 10.1128/AAC.44.4.1102-1107.2000.
9
Pharmacokinetics and pharmacodynamics of fluoroquinolones.氟喹诺酮类药物的药代动力学和药效学
Drugs. 1999;58 Suppl 2:29-36. doi: 10.2165/00003495-199958002-00006.
10
Activity of newer fluoroquinolones in vitro against gram-positive bacteria.新型氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1999;58 Suppl 2:23-8. doi: 10.2165/00003495-199958002-00005.
本文引用的文献
1
Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.克林沙星的药代动力学和炎性液体渗透情况
Antimicrob Agents Chemother. 1998 Feb;42(2):428-30. doi: 10.1128/AAC.42.2.428.
2
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.健康受试者中克林沙星（CI-960）的耐受性和药代动力学
J Antimicrob Chemother. 1996 Dec;38(6):1023-9. doi: 10.1093/jac/38.6.1023.
3
In vitro susceptibility of anaerobes to quinolones in the United States.美国厌氧菌对喹诺酮类药物的体外敏感性
Clin Infect Dis. 1996 Dec;23 Suppl 1:S2-8. doi: 10.1093/clinids/23.supplement_1.s2.
4
The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.克林沙星与其他抗菌药物对万古霉素敏感和耐药肠球菌的体外比较活性。
Chemotherapy. 1996 Jul-Aug;42(4):235-9. doi: 10.1159/000239449.
5
In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.克林沙星、CI-990（PD 131112）和PD 138312对肠球菌的体外和体内活性
Antimicrob Agents Chemother. 1995 Sep;39(9):2123-7. doi: 10.1128/AAC.39.9.2123.
6
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.123株嗜麦芽窄食单胞菌对克林沙星、PD 131628、PD 138312、PD 140248、环丙沙星和氧氟沙星的敏感性。
Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. doi: 10.1128/AAC.38.2.369.
7
In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.克林沙星（CI-960）和PD 131628-2对厌氧菌的体外活性
J Antimicrob Chemother. 1994 Oct;34(4):579-84. doi: 10.1093/jac/34.4.579.
8
Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.耐环丙沙星葡萄球菌和肠球菌对克林沙星的敏感性
Diagn Microbiol Infect Dis. 1995 Jan;21(1):27-31. doi: 10.1016/0732-8893(94)00143-k.
9
Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.在使用一组耐环丙沙星临床分离株进行挑战研究后，对克林沙星（CI-960、AM-1091、PD127371）和氟罗沙星（Ro 23-6240、AM-833）的纸片扩散药敏试验标准的修改。
Diagn Microbiol Infect Dis. 1995 Apr;21(4):209-13. doi: 10.1016/0732-8893(94)00061-z.
10
Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.三种研究性氟喹诺酮类药物（BAY y 3118、DU-6859a和克林沙星）对环丙沙星和氧氟沙星敏感性降低的淋病奈瑟菌分离株的活性。
Antimicrob Agents Chemother. 1995 Jul;39(7):1606-8. doi: 10.1128/AAC.39.7.1606.
Zotero 插件